Lori Brisbin, vice president of precision medicine at Texas Oncology, discusses using Trapelo, an automated tool to track precision medicine guidelines in various cancers, in patients with ovarian cancer.

In 2019, Trapelo was in a beta trial with 50 different physicians, ranging from those who practice precision medicine frequently to those who are less familiar, explains Brisbin. Ovarian cancer testing standards were added to this tool with the emergence of PARP inhibitors, which made it necessary to perform molecular tests on patients with ovarian cancer to find those with 

Guidelines for performing genetic testing on patients with ovarian cancer are complicated, which is why Trapelo may be useful to physicians in their daily practice, according to Brisbin. Trapelo will help answer questions such as, “Should we do germline or somatic testing?” and “What phase of the disease and in what setting of disease management should we test?” The ovarian cancer guidelines are different than the breast cancer guidelines, which Trapelo will help track, concludes Brisbin.

Videos

Lori Brisbin, discusses using Trapelo, an automated tool to track precision medicine guidelines in various cancers, in patients with ovarian cancer.

Using Trapelo to Maintain Molecular Testing Guidelines for Ovarian Cancer

Lori Brisbin, vice president of precision medicine at Texas Oncology, discusses Trapelo, a new automated tool to help increase the number of patients who receive molecular testing as a precision medicine effort.

Trapelo is a decision support tool that assists in choosing the best test for patients based on their tumor type, explains Brisbin. The tool is updated every day with guidelines from the National Comprehensive Cancer Network, ASCO, and the FDA. People can also input information on clinical trials to help identify eligible patients, according to Brisbin.

The purpose of Trapelo is to increase the number of patients who receive molecular testing because, currently, only 30% of patients are receiving molecular testing, says Brisbin. This tool will advise which patients to test because each disease has different standards. For example, patients with breast cancer typically receive testing throughout the disease course, but patients with lung cancer are tested during stage III and metastatic stage IV disease. Community oncologists who work with several different tumor types struggle to keep track of information regarding testing for each disease, but Trapelo should offer a quick way to check the most up-to-date guidelines, concludes Brisbin.

Lori Brisbin, discusses Trapelo, a new automated tool to help increase the number of patients who receive molecular testing as a precision medicine effort.

Lori Brisbin

Articles

Using Trapelo to Maintain Molecular Testing Guidelines for Ovarian Cancer

Utility of Trapelo to Increase Molecular Testing Rates